102 related articles for article (PubMed ID: 27324042)
21. ERK-MAP Kinase signaling in the cytoplasm.
Mendoza MC; Er EE; Blenis J
Methods Mol Biol; 2010; 661():185-203. PubMed ID: 20811984
[TBL] [Abstract][Full Text] [Related]
22. The N-terminal region of p27 inhibits HIF-1α protein translation in ribosomal protein S6-dependent manner by regulating PHLPP-Ras-ERK-p90RSK axis.
Zhang D; Liu J; Mi X; Liang Y; Li J; Huang C
Cell Death Dis; 2014 Nov; 5(11):e1535. PubMed ID: 25412313
[TBL] [Abstract][Full Text] [Related]
23. Structural assembly of the signaling competent ERK2-RSK1 heterodimeric protein kinase complex.
Alexa A; Gógl G; Glatz G; Garai Á; Zeke A; Varga J; Dudás E; Jeszenői N; Bodor A; Hetényi C; Reményi A
Proc Natl Acad Sci U S A; 2015 Mar; 112(9):2711-6. PubMed ID: 25730857
[TBL] [Abstract][Full Text] [Related]
24. p90Rsk is required for G1 phase arrest in unfertilized starfish eggs.
Mori M; Hara M; Tachibana K; Kishimoto T
Development; 2006 May; 133(9):1823-30. PubMed ID: 16571626
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of ERK-MAP kinase signaling by RSK during Drosophila development.
Kim M; Lee JH; Koh H; Lee SY; Jang C; Chung CJ; Sung JH; Blenis J; Chung J
EMBO J; 2006 Jul; 25(13):3056-67. PubMed ID: 16763554
[TBL] [Abstract][Full Text] [Related]
26. A non-catalytic herpesviral protein reconfigures ERK-RSK signaling by targeting kinase docking systems in the host.
Alexa A; Sok P; Gross F; Albert K; Kobori E; Póti ÁL; Gógl G; Bento I; Kuang E; Taylor SS; Zhu F; Ciliberto A; Reményi A
Nat Commun; 2022 Jan; 13(1):472. PubMed ID: 35078976
[TBL] [Abstract][Full Text] [Related]
27. Biochemical and biological functions of the N-terminal, noncatalytic domain of extracellular signal-regulated kinase 2.
Eblen ST; Catling AD; Assanah MC; Weber MJ
Mol Cell Biol; 2001 Jan; 21(1):249-59. PubMed ID: 11113199
[TBL] [Abstract][Full Text] [Related]
28. Manipulation of pro-inflammatory cytokine production by the bacterial cell-penetrating effector protein YopM is independent of its interaction with host cell kinases RSK1 and PRK2.
Höfling S; Scharnert J; Cromme C; Bertrand J; Pap T; Schmidt MA; Rüter C
Virulence; 2014; 5(7):761-71. PubMed ID: 25513777
[TBL] [Abstract][Full Text] [Related]
29. Mechanism of sustained activation of ribosomal S6 kinase (RSK) and ERK by kaposi sarcoma-associated herpesvirus ORF45: multiprotein complexes retain active phosphorylated ERK AND RSK and protect them from dephosphorylation.
Kuang E; Wu F; Zhu F
J Biol Chem; 2009 May; 284(20):13958-13968. PubMed ID: 19304659
[TBL] [Abstract][Full Text] [Related]
30. CCAAT-enhancer-binding protein beta activation of MMP-1 gene expression in SW1353 cells: independent roles of extracellular signal-regulated and p90/ribosomal S6 kinases.
Petrella BL; Armstrong DA; Vincenti MP
J Cell Physiol; 2011 Dec; 226(12):3349-54. PubMed ID: 21344389
[TBL] [Abstract][Full Text] [Related]
31. RSK2 and its binding partners in cell proliferation, transformation and cancer development.
Cho YY
Arch Pharm Res; 2017 Mar; 40(3):291-303. PubMed ID: 28013489
[TBL] [Abstract][Full Text] [Related]
32. Involvement of ERK-RSK cascade in phenylephrine-induced phosphorylation of GATA4.
Li T; Liu Z; Hu X; Ma K; Zhou C
Biochim Biophys Acta; 2012 Feb; 1823(2):582-92. PubMed ID: 22227582
[TBL] [Abstract][Full Text] [Related]
33. Identification of novel extracellular signal-regulated kinase docking domain inhibitors.
Hancock CN; Macias A; Lee EK; Yu SY; Mackerell AD; Shapiro P
J Med Chem; 2005 Jul; 48(14):4586-95. PubMed ID: 15999996
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic targeting of p90 ribosomal S6 kinase.
Wright EB; Lannigan DA
Front Cell Dev Biol; 2023; 11():1297292. PubMed ID: 38169775
[TBL] [Abstract][Full Text] [Related]
35. Novel potent and selective inhibitors of p90 ribosomal S6 kinase reveal the heterogeneity of RSK function in MAPK-driven cancers.
Aronchik I; Appleton BA; Basham SE; Crawford K; Del Rosario M; Doyle LV; Estacio WF; Lan J; Lindvall MK; Luu CA; Ornelas E; Venetsanakos E; Shafer CM; Jefferson AB
Mol Cancer Res; 2014 May; 12(5):803-12. PubMed ID: 24554780
[TBL] [Abstract][Full Text] [Related]
36. RSK promotes G2 DNA damage checkpoint silencing and participates in melanoma chemoresistance.
Ray-David H; Romeo Y; Lavoie G; Déléris P; Tcherkezian J; Galan JA; Roux PP
Oncogene; 2013 Sep; 32(38):4480-9. PubMed ID: 23108403
[TBL] [Abstract][Full Text] [Related]
37. Paving the way for targeting RSK in cancer.
Romeo Y; Roux PP
Expert Opin Ther Targets; 2011 Jan; 15(1):5-9. PubMed ID: 20958120
[TBL] [Abstract][Full Text] [Related]
38. A case of convergent evolution: Several viral and bacterial pathogens hijack RSK kinases through a common linear motif.
Sorgeloos F; Peeters M; Hayashi Y; Borghese F; Capelli N; Drappier M; Cesaro T; Colau D; Stroobant V; Vertommen D; de Bodt G; Messe S; Forné I; Mueller-Planitz F; Collet JF; Michiels T
Proc Natl Acad Sci U S A; 2022 Feb; 119(5):. PubMed ID: 35091472
[TBL] [Abstract][Full Text] [Related]
39. Two widely used RSK inhibitors, BI-D1870 and SL0101, alter mTORC1 signaling in a RSK-independent manner.
Roffé M; Lupinacci FC; Soares LC; Hajj GN; Martins VR
Cell Signal; 2015 Aug; 27(8):1630-42. PubMed ID: 25889895
[TBL] [Abstract][Full Text] [Related]
40. Spatially separate docking sites on ERK2 regulate distinct signaling events in vivo.
Dimitri CA; Dowdle W; MacKeigan JP; Blenis J; Murphy LO
Curr Biol; 2005 Jul; 15(14):1319-24. PubMed ID: 16051177
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
